hormona glp 1 y gip GLP-1 and in Type Diabetes Therapy: A Time for Reappraisal? Los agonistas del receptor GLP-1

TRIUMPH-1 was funded by Eli Lilly and Company

Long-Term Safety : While early results are promising, long-term safety and tolerability remain under investigation

Many patients use microdosing to maintain weight loss, reduce food noise, support blood sugar control, or explore other metabolic benefits while minimizing side effects

Long-term use may be required to maintain weight loss, which has cost and ongoing commitment implications

Regarding hypoglycaemia: as with other incretin-based therapies, the risk of low blood glucose with retatrutide alone is considered low, given its glucose-dependent mechanism of action

Providers weigh measurable criteria, such as BMI, alongside lifestyle factors, such as how someone has responded to diet and exercise in the past, before recommending a treatment plan